Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Apolipoprotein A refers to a group of structurally related proteins that are key components of lipoproteins, which transport lipids (fats) in the blood. The most clinically significant members are Apolipoprotein A-I (apoA-I) and Apolipoprotein A-II (apoA-II). ApoA-I is the major structural and functional protein component of high-density lipoprotein (HDL) and promotes reverse cholesterol transport. ApoA-II is the second most abundant protein in HDL after apoA-I and plays a role in HDL structure and remodeling. Deficiency or mutations in APOA1 gene can lead to familial HDL deficiencies. Low levels of apoA-I are associated with increased risk for cardiovascular disease.
N/A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Apolipoprotein A (ApoA).